A Boulder biotech working on genome engineering said it's raised $23 million in a Series B round of funding. Muse bio said the funding round was led by Venrock and included investments from Foresite Capital and Paladin Capital, and original investors NanoDimension and Spruce/MLS. "Muse bio's technology ...
Read More